CN108348556A - 细胞周期阻滞提高产生诱导多能干细胞的效率 - Google Patents
细胞周期阻滞提高产生诱导多能干细胞的效率 Download PDFInfo
- Publication number
- CN108348556A CN108348556A CN201680063137.9A CN201680063137A CN108348556A CN 108348556 A CN108348556 A CN 108348556A CN 201680063137 A CN201680063137 A CN 201680063137A CN 108348556 A CN108348556 A CN 108348556A
- Authority
- CN
- China
- Prior art keywords
- cell
- phases
- cell cycle
- inhibitor
- cycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002894 multi-fate stem cell Anatomy 0.000 title claims abstract description 22
- 230000025084 cell cycle arrest Effects 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 203
- 238000000034 method Methods 0.000 claims abstract description 83
- 230000022131 cell cycle Effects 0.000 claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 230000010190 G1 phase Effects 0.000 claims description 22
- 239000001963 growth medium Substances 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 20
- 210000000130 stem cell Anatomy 0.000 claims description 17
- 239000000975 dye Substances 0.000 claims description 14
- -1 Mei Weinuolin Chemical compound 0.000 claims description 12
- 230000018199 S phase Effects 0.000 claims description 12
- 230000035519 G0 Phase Effects 0.000 claims description 11
- 230000027311 M phase Effects 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 8
- 108091000080 Phosphotransferase Proteins 0.000 claims description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 8
- 102000020233 phosphotransferase Human genes 0.000 claims description 8
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 7
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 7
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 7
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 7
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 7
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 7
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 7
- 102100033254 Tumor suppressor ARF Human genes 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 7
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 7
- 230000029115 microtubule polymerization Effects 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 claims description 6
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 claims description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 6
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 6
- 230000011278 mitosis Effects 0.000 claims description 6
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000026683 transduction Effects 0.000 claims description 6
- 238000010361 transduction Methods 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 230000004668 G2/M phase Effects 0.000 claims description 5
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 5
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 5
- 206010027336 Menstruation delayed Diseases 0.000 claims description 5
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims description 5
- 229960004844 lovastatin Drugs 0.000 claims description 5
- 229950006344 nocodazole Drugs 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 claims description 5
- 229960000460 razoxane Drugs 0.000 claims description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 claims description 4
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims description 4
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 claims description 4
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 4
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 4
- 230000010355 oscillation Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 229940104230 thymidine Drugs 0.000 claims description 4
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 claims description 3
- LGFMXOTUSSVQJV-NEYUFSEYSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;1-[(3,4-dimethoxyphenyl)methyl]-6 Chemical compound Cl.Cl.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 LGFMXOTUSSVQJV-NEYUFSEYSA-N 0.000 claims description 3
- XOLMRFUGOINFDQ-YBEGLDIGSA-N (5z)-5-(quinolin-6-ylmethylidene)-2-(thiophen-2-ylmethylamino)-1,3-thiazol-4-one Chemical compound S1\C(=C/C=2C=C3C=CC=NC3=CC=2)C(=O)N=C1NCC1=CC=CS1 XOLMRFUGOINFDQ-YBEGLDIGSA-N 0.000 claims description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 3
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 claims description 3
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 3
- WZNJWVWKTVETCG-YFKPBYRVSA-N L-mimosine Chemical compound OC(=O)[C@@H](N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-YFKPBYRVSA-N 0.000 claims description 3
- 241000711408 Murine respirovirus Species 0.000 claims description 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 claims description 3
- 101710102803 Tumor suppressor ARF Proteins 0.000 claims description 3
- 229960003896 aminopterin Drugs 0.000 claims description 3
- PUAQLLVFLMYYJJ-ZETCQYMHSA-N cathinone Chemical compound C[C@H](N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-ZETCQYMHSA-N 0.000 claims description 3
- 229950002698 cathinone Drugs 0.000 claims description 3
- 229960005052 demecolcine Drugs 0.000 claims description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 3
- 229950002289 mimosine Drugs 0.000 claims description 3
- 108700024542 myc Genes Proteins 0.000 claims description 3
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 229960000604 valproic acid Drugs 0.000 claims description 3
- 101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 claims description 2
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 101150033269 ESRRG gene Proteins 0.000 claims description 2
- 101150099612 Esrrb gene Proteins 0.000 claims description 2
- 108091007911 GSKs Proteins 0.000 claims description 2
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- 101150072501 Klf2 gene Proteins 0.000 claims description 2
- 101710128836 Large T antigen Proteins 0.000 claims description 2
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 claims description 2
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 claims description 2
- 101100310650 Mus musculus Sox18 gene Proteins 0.000 claims description 2
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 claims description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims description 2
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 claims description 2
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 2
- 101150001847 Sox15 gene Proteins 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 101150111214 lin-28 gene Proteins 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 102000005234 Adenosylhomocysteinase Human genes 0.000 claims 1
- 108020002202 Adenosylhomocysteinase Proteins 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 229940124036 Hydrolase inhibitor Drugs 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000004093 hydrolase inhibitor Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 claims 1
- 229950006286 pentrinitrol Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000010307 cell transformation Effects 0.000 abstract 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 5
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 4
- 108010048992 Transcription Factor 4 Proteins 0.000 description 4
- 102100023489 Transcription factor 4 Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960001330 hydroxycarbamide Drugs 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 2
- 108010017123 Kruppel-Like Transcription Factors Proteins 0.000 description 2
- 102000004434 Kruppel-Like Transcription Factors Human genes 0.000 description 2
- 102100022978 Sex-determining region Y protein Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 229960004708 noscapine Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- ZESGNAJSBDILTB-OXVOKJAASA-N (2e,4s,5s,6e,8e)-10-[(2s,3r,6s,8r,9s)-3-butyl-2-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dienyl]-3-(3-carboxypropanoyloxy)-9-methyl-1,7-dioxaspiro[5.5]undecan-8-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid Chemical compound O1[C@@H](\C=C\C(\C)=C\C(O)=O)[C@](CCCC)(OC(=O)CCC(O)=O)CC[C@@]11O[C@H](C\C=C(/C)\C=C\[C@H](O)[C@@H](C)\C=C\C(O)=O)[C@@H](C)CC1 ZESGNAJSBDILTB-OXVOKJAASA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- MRPGRAKIAJJGMM-OCCSQVGLSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC(=CC=1)C(F)(F)F)Cl)=CC2=O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000723375 Colchicum Species 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 101150012532 NANOG gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- ZESGNAJSBDILTB-UHFFFAOYSA-N Reveromycin A Natural products O1C(C=CC(C)=CC(O)=O)C(CCCC)(OC(=O)CCC(O)=O)CCC11OC(CC=C(C)C=CC(O)C(C)C=CC(O)=O)C(C)CC1 ZESGNAJSBDILTB-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108700032475 Sex-Determining Region Y Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- 108010048999 Transcription Factor 3 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000973 gametocyte Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229950003294 voruciclib Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249520P | 2015-11-02 | 2015-11-02 | |
| US62/249,520 | 2015-11-02 | ||
| PCT/US2016/059112 WO2017079029A1 (en) | 2015-11-02 | 2016-10-27 | Cell cycle block improves efficiency in generating induced pluripotent stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108348556A true CN108348556A (zh) | 2018-07-31 |
Family
ID=58662634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680063137.9A Pending CN108348556A (zh) | 2015-11-02 | 2016-10-27 | 细胞周期阻滞提高产生诱导多能干细胞的效率 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3370744A4 (ja) |
| JP (1) | JP2018531610A (ja) |
| KR (1) | KR20180072817A (ja) |
| CN (1) | CN108348556A (ja) |
| IL (1) | IL258640A (ja) |
| WO (1) | WO2017079029A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531382A (zh) * | 2021-06-29 | 2022-12-30 | 中国科学院生物物理研究所 | 喹啉噻唑啉酮衍生物Ro-3306在治疗β-冠状病毒感染中的应用 |
| WO2023273882A1 (zh) * | 2021-06-30 | 2023-01-05 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 一种高效无遗传修饰的iPSC诱导、产业化单克隆挑取平台及应用 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107589002B (zh) * | 2017-09-08 | 2020-05-29 | 杭州市妇产科医院 | 一种诱导多能干细胞染色体的制备方法 |
| US20220267736A1 (en) * | 2017-12-28 | 2022-08-25 | Kaneka Corporation | Pluripotent stem cell aggregation suppressor |
| CN110016460A (zh) * | 2018-01-09 | 2019-07-16 | 中国农业大学 | 一种高效鸡胚胎原代成纤维细胞g2/m期同步化方法 |
| CN108531447B (zh) * | 2018-04-13 | 2021-11-23 | 上海市生物医药技术研究院 | 调节精子运动能力及辅助生殖的化合物及其用途 |
| WO2023243679A1 (ja) * | 2022-06-17 | 2023-12-21 | 学校法人日本医科大学 | 高力価ウイルスベクターの製造方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6033847A (en) * | 1995-02-06 | 2000-03-07 | St. Jude Children's Research Hospital | InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof |
| US20140056860A1 (en) * | 2011-04-08 | 2014-02-27 | Universite Montpellier Ii | Method for rejuvenating cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998032847A2 (en) * | 1997-01-23 | 1998-07-30 | The Johns Hopkins University School Of Medicine | Characterization of the yeast transcriptome |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US9238797B2 (en) * | 2008-07-07 | 2016-01-19 | Takara Bio Inc. | Method for production of pluripotent stem cell |
| US20120076762A1 (en) * | 2009-03-25 | 2012-03-29 | The Salk Institute For Biological Studies | Induced pluripotent stem cell generation using two factors and p53 inactivation |
| JP2013510576A (ja) * | 2009-11-11 | 2013-03-28 | サンフォード−バーンハム メディカル リサーチ インスティテュート | ｉＰＳ細胞の生成および調節のための方法およびその組成物 |
| CN104278008B (zh) * | 2013-07-12 | 2020-08-21 | 北京宏冠再生医学科技有限公司 | 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途 |
| JP6232907B2 (ja) * | 2013-10-09 | 2017-11-22 | 富士レビオ株式会社 | 融合細胞およびその作製方法 |
-
2016
- 2016-10-27 EP EP16862739.6A patent/EP3370744A4/en not_active Withdrawn
- 2016-10-27 CN CN201680063137.9A patent/CN108348556A/zh active Pending
- 2016-10-27 JP JP2018521503A patent/JP2018531610A/ja active Pending
- 2016-10-27 WO PCT/US2016/059112 patent/WO2017079029A1/en active Application Filing
- 2016-10-27 KR KR1020187015171A patent/KR20180072817A/ko unknown
-
2018
- 2018-04-11 IL IL258640A patent/IL258640A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6033847A (en) * | 1995-02-06 | 2000-03-07 | St. Jude Children's Research Hospital | InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof |
| US20140056860A1 (en) * | 2011-04-08 | 2014-02-27 | Universite Montpellier Ii | Method for rejuvenating cells |
Non-Patent Citations (2)
| Title |
|---|
| CHRISTOPH SCHORL等: "Analysis of cell cycle phases and progression in cultured mammalian cells", 《METHODS》 * |
| R W ALLEN等: "Arrest of cell growth in the G1 phase of the cell cycle by serine deprivation", 《EXPERIMENTAL CELL RESEARCH》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531382A (zh) * | 2021-06-29 | 2022-12-30 | 中国科学院生物物理研究所 | 喹啉噻唑啉酮衍生物Ro-3306在治疗β-冠状病毒感染中的应用 |
| CN115531382B (zh) * | 2021-06-29 | 2024-01-30 | 中国科学院生物物理研究所 | 喹啉噻唑啉酮衍生物Ro-3306在治疗β-冠状病毒感染中的应用 |
| WO2023273882A1 (zh) * | 2021-06-30 | 2023-01-05 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 一种高效无遗传修饰的iPSC诱导、产业化单克隆挑取平台及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018531610A (ja) | 2018-11-01 |
| KR20180072817A (ko) | 2018-06-29 |
| EP3370744A1 (en) | 2018-09-12 |
| WO2017079029A1 (en) | 2017-05-11 |
| IL258640A (en) | 2018-06-28 |
| EP3370744A4 (en) | 2019-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108348556A (zh) | 细胞周期阻滞提高产生诱导多能干细胞的效率 | |
| US20160251629A1 (en) | Compositions and methods for reprogramming eukaryotic cells | |
| KR102675213B1 (ko) | 망막 색소 표피 세포의 제조 방법 | |
| AU2016318774B2 (en) | MACS-based purification of stem cell-derived retinal pigment epithelium | |
| US20210238546A1 (en) | Method for differentiation of ocular cells and use thereof | |
| EP2295538B1 (en) | Method for production of pluripotent stem cell | |
| Michelotti et al. | Trypanosoma brucei mitochondrial ribosomal RNA synthesis, processing and developmentally regulated expression | |
| JP7173496B2 (ja) | 心筋細胞への分化指向性を有する多能性幹細胞を選抜するための方法 | |
| WO2019217493A2 (en) | Cell populations and gene expression associated with in vitro beta cell differentiation | |
| JPWO2019189545A1 (ja) | 細胞の製造方法 | |
| JP5636174B2 (ja) | 間葉系細胞または軟骨細胞の製法ならびに発癌性の抑制方法 | |
| WO2016161023A1 (en) | Methods to isolate high quality rna from fixed samples | |
| US20220235329A1 (en) | Methods for generating induced pluripotent stem cells via cell cycle synchronization | |
| WO2021182477A1 (en) | Markers specific for pluripotent stem cells, and methods of using the same | |
| JP7141043B2 (ja) | 人工多能性幹細胞の評価方法及び選抜方法、並びに人工多能性幹細胞の製造方法 | |
| JP6516280B2 (ja) | ｉＰＳ細胞の樹立方法および幹細胞の長期維持方法 | |
| CN108601801A (zh) | 基于鉴别和改善肝功能障碍来诊断和治疗帕金森病 | |
| US20230339983A1 (en) | Fluorescent compounds specific for pluripotent stem cells and reprogramming-ready cells and methods of using the same | |
| CN116925999A (zh) | 一种快速鉴别iPSC与EPSC的方法 | |
| Xiong et al. | Differentiation of induced pluripotent stem cells for future olfactory repair using an indirect co-culture technique | |
| Urrutia-Cabrera et al. | Combinatorial approach of binary colloidal crystals (BCCs) and CRISPR activation to improve induced pluripotent stem cell differentiation into neurons | |
| Lange et al. | Generation of a human induced pluripotent stem cell line (UMGACBi001-A) from urine cells of a chronic kidney disease patient with hypertension, diabetic nephropathy and acute sepsis | |
| JP2024510965A (ja) | 多能性幹細胞に特異的なマーカー及びその使用方法 | |
| Carter | Investigating the Role of the T-Cell Receptor Using Targeted Capture and High-Throughput Sequencing | |
| WO2019150891A1 (ja) | 未分化細胞の状態を評価する方法及びその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1259167 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180731 |